Publications by authors named "R DeBiasio"
Article Synopsis
- The study suggests that insulin resistance in the liver is a key factor leading to dysfunction in pancreatic islets, which is linked to Type 2 Diabetes Mellitus (T2DM) and Metabolic Associated Steatotic Liver Disease (MASLD).
- Researchers developed a microphysiological system combining liver and pancreatic models to better understand how these organ dysfunctions relate to each other. This system allows for the investigation of changes that occur when metabolic syndrome is present.
- Results showed that under metabolic syndrome conditions, the liver-pancreas system exhibited altered insulin secretion and signaling, indicating a direct connection between liver issues and islet dysfunction, which could help in developing personalized treatment strategies for affected patients.
Article Synopsis
- - MASLD is a global health issue affecting around 30% of the population, caused by a mix of genetics, lifestyle, and environmental factors, posing challenges for treatment development due to patient variability.
- - Creating effective therapeutic models is difficult because existing systems and animal models fail to fully reflect the complexities of MASLD progression, prompting the need for more precise experimental approaches.
- - The study utilized a liver acinus microphysiology system (LAMPS) with patient-derived cells to explore the effects of the PNPLA3 genetic variant on MASLD and tested the drug resmetirom, revealing significant changes in liver cell behavior indicative of disease progression.
Article Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of the global population, driven by a mix of genetic, lifestyle, and environmental factors, complicating treatment and clinical trial design.* -
- The study utilized a liver acinus microphysiology system (LAMPS) made from patient-derived cells to explore the effects of the PNPLA3 rs738409 genetic variant on MASLD progression, replicating various metabolic conditions.* -
- Results showed that the PNPLA3 GG variant led to increased liver fat, immune activation, and pro-fibrotic factor secretion compared to wild type cells, providing insights for future treatments like resmetirom.*
Article Synopsis
- Researchers found that problems in the liver can lead to issues in the pancreas, which affects blood sugar levels and can cause diabetes and a liver disease called MASLD.
- They created a special system that mimics human organs to study how these two organs affect each other when things go wrong, like during early metabolic syndrome.
- The results showed that when the liver is not working properly, it can send confusing signals to the pancreas, making it harder for the body to control insulin and blood sugar, which could help doctors understand these diseases better and create personalized treatments.
Non-alcoholic fatty liver disease (NAFLD) has a high global prevalence with a heterogeneous and complex pathophysiology that presents barriers to traditional targeted therapeutic approaches. We describe an integrated quantitative systems pharmacology (QSP) platform that comprehensively and unbiasedly defines disease states, in contrast to just individual genes or pathways, that promote NAFLD progression. The QSP platform can be used to predict drugs that normalize these disease states and experimentally test predictions in a human liver acinus microphysiology system (LAMPS) that recapitulates key aspects of NAFLD.
View Article and Find Full Text PDF